| S6681 |
Paricalcitol
|
Paricalcitol is a selective Vitamin D receptor agonist. This compound suppresses parathyroid hormone mRNA expression and inhibits parathyroid cell proliferation. It is used to treat secondary hyperparathyroidism in chronic kidney disease.
|
-
Redox Biol, 2025, 80:103518
-
Redox Biol, 2024, 70:103062
-
Front Pharmacol, 2024, 15:1421577
|
|
| S1466 |
Calcitriol (1,25-Dihydroxyvitamin D3)
|
Calcitriol is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol. Solutions are unstable and should be fresh-prepared.
|
-
Cell Commun Signal, 2025, 23(1):104
-
Cancer Sci, 2025, 116(7):1871-1882
-
Cureus, 2025, 17(4):e82934
|
|